UNICREDIT BANK/CALL/ROCHE GS/300/0.1/17.12.25 | Real-time BOERSE MUENCHEN 18:46:45 08/07/2024 BST | ||
| 0.65 EUR | -2.99% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ROCHE HOLDING AG
| Date | Price | Change |
|---|---|---|
| 08/07/24 | 0.65 | -2.99% |
| 05/07/24 | 0.67 | +4.69% |
| 04/07/24 | 0.64 | -9.86% |
| 03/07/24 | 0.71 | -4.05% |
| 02/07/24 | 0.74 | -5.13% |
Real-time BOERSE MUENCHEN
Last update July 08, 2024 at 06:46 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ROCHE HOLDING AG |
| Issuer | 
UniCredit
|
| WKN | HD6SQD |
| ISIN | DE000HD6SQD6 |
| Date issued | 01/07/2024 |
| Strike | 300 CHF |
| Maturity | 17/12/2025 (527 Days) |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.82 € |
|---|---|
| Lowest since issue | 0.59 € |
| Delta | 0.2x |
| Omega | 7.976 |
| Premium | 25.65x |
| Gearing | 39.18x |
| Moneyness | 0.8123 |
| Difference Strike | 56.3 CHF |
| Difference Strike % | +18.77% |
| Spread | 0.04 € |
| Spread % | 6.06% |
| Theoretical value | 0.6350 |
| Implied Volatility | 20.60 % |
| Total Loss Probability | 85.82 % |
| Intrinsic value | 0.000000 |
| Present value | 0.6350 |
| Break even | 306.17 € |
| Theta | -0.01x |
| Vega | 0.08x |
| Rho | 0.06x |
Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
Consensus: Roche Holding AG
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.3
CHF
Average target price
276.6
CHF
Spread / Average Target
+13.70%
- Stock Market
- Warrants
- Warrant
